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Background: Today it is unclear which technique for delivery of an additional boost after whole breast
radiotherapy for breast conserved patients should be state of the art. We present a dosimetric comparison of
different non-invasive treatment techniques for additional boost delivery.
Methods: For 10 different tumor bed localizations, 7 different non-invasive treatment plans were made. Dosimetric
comparison of PTV-coverage and dose to organs at risk was performed.
Results: The Vero system achieved an excellent PTV-coverage and at the same time could minimize the dose to the
organs at risk with an average near-maximum-dose (D2) to the heart of 0.9 Gy and the average volume of ipsilateral
lung receiving 5 Gy (V5) of 1.5%. The TomoTherapy modalities delivered an average D2 to the heart of 0.9 Gy for the
rotational and of 2.3 Gy for the static modality and an average V5 to the ipsilateral lung of 7.3% and 2.9% respectively.
A rotational technique offers an adequate conformity at the cost of more low dose spread and a larger build-up area.
In most cases a 2-field technique showed acceptable PTV-coverage, but a bad conformity. Electrons often delivered a
worse PTV-coverage than photons, with the planning requirements achieved only in 2 patients and with an average
D2 to the heart of 2.8 Gy and an average V5 to the ipsilateral lung of 5.8%.
Conclusions: We present advices which can be used as guidelines for the selection of the best individualized
treatment.
Keywords: Breast cancer, Tumor bed boost, Image guided radiation treatment (IGRT), Intensity modulated
radiotherapy (IMRT), TomoTherapy, VeroBackground
Postoperative irradiation after breast conserving surgery
(BCS) for breast cancer has shown a gain in recurrence
free and overall survival [1-9]. An additional boost to
the initial tumor bed has shown an additional gain in re-
currence free survival [10]. In the last decades, a lot of
attention has gone to the development of new techniques
to reduce side effects. In case of breast irradiation this
means late side effects on skin, heart and lungs. With this
evolution, several techniques to deliver a boost dose to
the initial tumor bed have become available. Historically
the boost dose mainly was delivered by electrons. To
date, it is unclear which technique should be preferred. A* Correspondence: hilde.vanparijs@uzbrussel.be
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reproduction in any medium, provided the orcomparison of the boost techniques used in the EORTC
'boost versus no boost' trial showed no significant differ-
ence between electron, photon or interstitial boost in
terms of fibrosis and local control [11,12]. But it was not
the primary goal of this trial to investigate different out-
come with different boost techniques. Differences within
several photon boost techniques have not been investi-
gated. It was our objective to make a dosimetric compari-
son of different non-invasive treatment techniques for
additional boost delivery to offer an individualized best
treatment to breast conserved patients.Methods
From a pool of available CT scans of early breast cancer
patients treated in an earlier trial [13], 10 situations were
selected. In this selection left and right breast cancerral Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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located in each of the 4 different quadrants and a cen-
trally located tumor was chosen. Within this selection,
attention was given to select small as well as larger boost
volumes, small as well as larger breast volumes and
deeply as well as superficially located tumors.
A 'CTVboost' was drawn to include the site of the pri-
mary tumor, according to pre-operative imaging of the
breast and according to the visual seroma and/or fibrosis
on post-operative CT, with a margin of 7 mm in all di-
rections to encompass potential microscopic disease
extension. When present, surgical clips were to be within
the CTVboost. The CTVboost excluded the skin, pectora-
lis muscle, ribs, lung and heart. PTVboost to CTVboost
margin was 6 mm in all directions, but limited at the skin.
The PTVboost, which could extend beyond the pectoralis
major muscle/breast tissue interface, was used for deter-
mining the aperture of the treatment fields. A 'PTVboost-
eval' was defined as the PTVboost limited at 5 mm below
the skin surface. The PTVboost-eval was used for generat-
ing dose volume histograms (DVH) and comparative ana-
lyses. A margin of 5 mm was chosen to minimize the
contribution of the dose build-up area at the skin. As or-
gans at risk (OAR) the ipsilateral lung, heart, ipsilateral
breast and contralateral breast were contoured.
Multiple treatment approaches were deployed for each
CT set to deliver a dose of 16 Gy in 8 fractions of 2 Gy,
which is the dose we prescribe in daily clinical practice in
our department based on the EORTC boost versus no
boost trial [12]. For each situation, all of following tech-
niques were planned: electrons, a photon boost with 2 and
3 static fields and a photon boost with dynamic conformal
arc using the CMS XIO planning software (Elekta AB,
Stockholm, Sweden), a photon boost with the Vero® system
(joint product of BrainLAB; BrainLAB AG, Feldkirchen,
Germany and MHI; Mitsubishi Heavy Industries, Tokyo,
Japan) [14], which has the possibility to turn the ring-
gantry from 30 to 330 degrees towards the table, a photon
boost with the TomoTherapy® system using rotational
IMRT, as well as the static application (TomoDirect®) for
tangential IMRT (Accuray Inc., Madison, USA) (Table 1).Table 1 Used planning software
Technique Planning software
Electrons CMS XIO V4.64
Photons with 2 static fields CMS XIO Release V4
Photons with 3 static fields CMS XIO Release V4
Photons with dynamic arc CMS XIO Release V4
Vero® iPlan RT Dose 4.1.2 f
Photons with rotational IMRT (TomoTherapy®) TomoTherapy Plann
Photon boost with tangential IMRT (TomoDirect®) TomoTherapy Plann
Planning software per technique and corresponding type of calculation algorithm [The planning aims were to cover 95% of the volume of
the PTVboost with at least 95% of the prescribed dose,
but not more than 107%. For all OAR, except for the
ipsilateral breast, the volume receiving 5 Gy should not
exceed 5%. For the ipsilateral breast there were no con-
straints, since today it is unclear which degree of dose
spread within the breast should be considered as Ac-
ceptable. As an alternative to using constraints, several
measurements for conformity were used. As a measure
of low dose spread the ratio of the volume of the 20%
isodose to the 95% isodose (Vol20/Vol95) and to the
ratio of the volume of the 50% isodose to the 95% isodose
(Vol50/Vol95) were registered. As a measure of con-
formity the conformity index (CI) was calculated, using the
following formula [16]:
CI ¼ TV PIV
2
TVPIV
TV ¼ target volume
PIV ¼ prescription dose volume
TVPIV ¼ overlap of TV and PIV
In this setting the TV is the PTVboost-eval, the PIV is
the 95% isodose of 16 Gy.
Figure 1 shows the different planning techniques. For
the electrons 1 beam perpendicular to the breast was
used. The aperture of this beam was a rectangular
shaped block surrounding the PTVboost to encompass it
with the 95% isodose. The energy was chosen to reach
the deepest point of the PTVboost with the 95% isodose.
Available energies were in the range of 6 to 15 MeV. For
the photon boost with 2 static fields either 2 tangential
or 2 wedged fields could be used, depending on the
localization of the PTVboost. When using the 3-field
technique a perpendicular field to the breast was added
to 2 tangential fields. For the planning on Vero 2 con-
formal tangential fields (ring 0°) were chosen to cover the
PTVboost and avoid as much as possible the ipsilateral
lung, heart and contralateral breast. Afterwards 2 more
beams per tangential beam were added with the same
gantry angle but different ring rotation (30° and 330°). As
last part more conformal beams and compensation fields
were added to reach a conformal dose distribution with a






ing Station H-Art Version 4.0.5 b
ing Station H-Art Version 4.0.5 b
15].
Figure 1 Dose distribution for 1 patient for all techniques. The dose distribution for 1 patient for all techniques: (a) electrons, (b) 2
tangential fields, (c) 3 fields, (d) arc, (e) Tomotherapy, (f) Tomodirect, (g) Vero.
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able. A treatment with 10 beams can take up to 25 mi-
nutes. TomoTherapy combines a rotational IMRT with a
translational movement of the couch. Blocking structures
and working volumes were used as was published earlier
[17]. TomoDirect is the static application of TomoTherapy,
where the gantry can be fixed at pre-chosen angles. Four
tangential beams and 1 beam perpendicular to the breast
were used to conform the dose.
Results
Ten CT scans were selected for analysis. For both left
and right side, a primary tumor location in each of the 4
quadrants was present, as well as a centrally located pri-
mary tumor bed. The pathological T-stage ranged from
T1b to T2. The mean maximal diameter of the tumorwas 1.6 cm (range: 0.6 - 2.7 cm). In 3 patients the dee-
pest border of the tumor was located more than 3.5 cm
from the skin surface. In only 1 patient the PTVboost
did not reach the skin surface. The mean PTV volume
was 71.73 cc (range: 24.91 - 137.88 cc). The mean vol-
ume of the ipsilateral breast was 447.92 cc (range:
108.66 - 865.74 cc). The mean PTV to ipsilateral breast
ratio was 19.6% (range: 7.8% - 34.2%) with 2 patients
having a ratio of more than 30%, 2 patients between
20 and 30%, 5 patients between 10 and 20% and 1 patient
with a ratio of less than 10%. Not all 10 tumor localizations
were clinically acceptable for electron boost delivery. In 2
patients the tumor was located too deep to cover the PTV
with 15 MeV electrons. In the 3rd patient the tumor bed
was located in the lateral breast fold. In practice, this
patient would have been repositioned for electron boost
Table 3 conformity index (CI): distribution per interval
of 10%
CI 1 2 3 4 5 6 7
<50% 4 9 0 0 0 0 0
50–59% 4 1 0 1 0 4 5
60–69% 2 0 5 5 5 6 4
≥70% 0 0 5 4 5 0 1
Conformity index for the different techniques, distribution per interval of 10%:
(1) electrons, (2) 2 tangential fields, (3) 3 static fields, (4) arc, (5) Vero,
(6) TomoTherapy, (7) TomoDirect.
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ric comparison. For the goal of the comparison a dose dis-
tribution was calculated for all 10 CT sets, but for the
interpretation of the further results, we should keep in
mind that there are 3 irrelevant situations present.
The PTV coverage (95% of the PTV volume receiving
95% of the prescription dose) was achieved in 2 patients
with electrons, in 7 with the 2-field photon boost, in 4
with the 3-field and the dynamic conformal arc photon
boost and in all 10 patients with the rotational and static
TomoTherapy modalities and Vero. The reason for fail-
ing to reach the PTV coverage criteria for the 2-field,
3-field and rotational photon boost, often was the build-
up. The mean build-up was more than 5 mm for the 2-
field, 3-field and dynamic conformal arc photon technique,
was slightly less than 5 mm for Vero and electrons
and was close to zero for the TomoTherapy modalities
(Table 2). The CI was equal to or more than 60% in 2 pa-
tients with electrons, in none of the 2-field photon boost
plans, in all 10 of the 3-field photon boost plans and Vero,
in 9 of the dynamic arc plans, in 6 of the rotational and in
5 of the tangential TomoTherapy plans (Table 3). Today
there is no literature available that gives an idea of which
CI is acceptable. From this analysis, our conclusion is that
a CI of 70% or more can be considered as excellent,
between 60% and 70% as good, between 50% and 60% as
acceptable and less than 50% as bad. The mean Vol50/
Vol95 was more than 4 with the 3-field photon technique
and with the tangential TomoTherapy technique, meaning
that for these 2 modalities more than 4 times the volume
of the actual target received an over-dosage of 50% of theTable 2 Dose comparison
1 2
PTV mean (sd) (Gy) 16,17 (0,27) 16,13 (0,48)
V95% (%) 79,91 94,44
CI (%) 47 (2–63) 39 (21–57)
Vol50/Vol95 3,62 2,90
Vol20/Vol95 11,90 6,42
Mean build-up (mm) 4.6 5.7
Heart mean (sd) 0,36 (0,67) 0,05 (0,10)
D2 (Gy) 2,75 0,33
V5 (%) 1,20 0,00
Ipsilat lung mean (sd) (Gy) 0,97 (1,97) 0,47 (1,41)
V5 (%) 5,84 2,83
V8 (%) 3,09 1,92
V15 (%) 0,12 0,25
Contralat breast mean (sd) (Gy) 0,00 (0,00) 0,02 (0,03)
D2 (Gy) 0,00 0,10
Summary of dose comparison: (1) electrons, (2) 2 tangential fields, (3) 3 static fields
in the 9 patients with PTV reaching the skin.prescribed dose or an over-dosage of 16% to the surround-
ing tissue, already treated to 50 Gy. Low dose spread was
more present with dynamic arc photon boost and the
TomoTherapy modalities, with a mean Vol20/Vol95 of
more than 10. For the other techniques this ratio ranged
between 5.8 and 9.6.
The near-maximum-dose (D2) [18] to the heart for all
techniques was below 5 Gy, except for 2 electron boost
plans. One of these plans belonged to a patient who would,
in good clinical practice, not have been a good candidate
for electron boost delivery, because of the deep localization
of the tumor bed. A rotational technique tends to deliver
slightly more dose to the ipsilateral lung. Vero was the only
technique which could keep the V5 for the ipsilateral lung
below 5% in all cases. The arc technique with CMS and
TomoTherapy delivered a mean V5 of 9% and 7% respect-
ively, with electrons (not considering the 3 bad candidates)
a mean V5 of 5% was delivered, for the other techniques
the V5 ranged from 1.5 to 4% (Table 2).3 4 5 6 7
16,02 (0,44) 15,98 (0,50) 16,07 (0,35) 16,17 (0,27) 16,07 (0,25)
94,51 93,15 96,70 97,58 97,90
69 (60–84) 67 (54–73) 70 (64–78) 59 (50–66) 61 (54–82)
4,91 3,86 3,22 3,62 4,42
9,59 11,95 7,97 11,90 10,93
6.4 7.2 4.5 2.2 2.1
0,47 (0,69) 0,80 (0,68) 0,23 (0,25) 0,15 (0,20) 0,54 (0,64)
2,48 2,68 0,94 0,85 2,26
0,27 0,43 0,00 0,02 0,01
1,09 (1,85) 1,62 (1,98) 0,55 (1,01) 1,44 (1,78) 1,02 (1,46)
4,18 9,01 1,49 7,32 2,85
2,17 3,38 0,65 2,56 1,26
0,18 0,11 0,01 0,09 0,07
0,01 (0,02) 0,31 (0,23) 0,05 (0,05) 0,04 (0,04) 0,05 (0,05)
0,07 0,81 0,25 0,15 0,20
, (4) arc, (5) Vero, (6) TomoTherapy, (7) TomoDirect; the build-up was evaluated
Table 4 Ranking
1 2 3 4 5 6 7
PTV V95 7 4 6 5 1 1 1
CI 6 7 2 3 1 5 4
Vol50/Vol95 3 1 7 5 2 3 6
Vol20/Vol95 5 1 3 5 2 5 4
Build-up 4 5 6 7 3 2 1
Heart D2 7 1 4 6 3 2 4
V5 7 1 5 6 1 1 1
Ipsilat lung V5 5 2 4 7 1 6 2
V8 6 3 4 7 1 5 2
Contralat breast D2 1 3 2 7 6 4 5
TOTAL SCORE 51 28 43 58 21 34 30
MEDIAN RANKING 5.5 2.5 4 6 1.5 3.5 3
Ranking of the different techniques according to the dose comparison,
techniques: (1) electrons, (2) 2 tangential fields, (3) 3 static fields, (4) arc,
(5) Vero, (6) TomoTherapy, (7) TomoDirect; scoring from 1 to 7, with 1
being the best score; the build-up was evaluated in the 9 patients with
PTV reaching the skin.
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breast with a near-maximum dose below 1.5 Gy. Only
when using electrons, zero doses were delivered in all
patients (Table 2).
Discussion
We report a dosimetric comparison of different non-
invasive techniques to deliver a boost dose after whole
breast irradiation as part of the breast conserving treat-
ment of breast cancer. We chose to select real cases for
this comparison. The cases were part of a patient popu-
lation of a phase III trial [13]. The target delineation was
performed at the moment of the actual treatment plan-
ning according to the protocol of the trial and not as
preparation for this work. This decreased the risk of un-
intentionally favoring a certain technique. With our se-
lection we wanted to get a an idea of the different
possibilities for a tumor localization in all of the four
quadrants or a centrally located tumor on both sides.
Within this selection we including small as well as larger
breasts, small as well as larger target volumes and super-
ficially as well as deeply located tumors.
A point of discussion could be the use of different
planning software systems for the different techniques.
Knöös reported a comparison of dose calculation algo-
rithms [15]. Algorithms were divided into 2 groups: type
a models, where changes in lateral transport of electrons
are not modeled, and type b models, that in an approxi-
mate way consider changes in lateral electron transport.
According to Knöös, the use of type b calculation algo-
rithms will in general reduce the uncertainty in the de-
livered dose to the patient. For this analysis all planning
software used type b calculation algorithms.
We concluded that Vero was the most promising tech-
nique, with the best median ranking (Table 3). The sec-
ond best median ranking was seen for the photon boost
with 2 fields. This was caused by a better sparing of
OAR, but was at the cost of a worse PTV coverage and
more dose spread to the already irradiated ipsilateral
breast. Assuming that the PTV coverage should be
the first concern, this "second place" is unjustified. Both
TomoTherapy modalities were also promising, with a
median ranking of 3 and 3.5. If paying even more atten-
tion to minimize the low dose spread, perhaps they could
score even better. This is of course the difficult choice
when using inverse planning systems. They are very
dependent on the effort you are willing to invest. Once
you achieve a clinical acceptable plan, do you accept it or
do you try to achieve even better? The extra effort and
time invested in further optimization of the dose distri-
bution should be balanced to the expected clinical im-
pact. In this work we compared only the boost dose of
16 Gy. Because, on itself, this is a low dose, less attention
could have gone to the low dose spread when planningwith TomoTherapy. The use of sophisticated IMRT-IGRT
linear accelerators increases the cost of radiation treatment
[19]. The expected clinical benefit should also be balanced
to the financial aspect. On top of that, we should keep in
mind that in clinical practice, a whole breast irradiation
was already performed. Even a low dose on top of 50 Gy
can be of clinical importance [20] (Table 4).
None of the used techniques seem significantly influ-
enced by respiratory movements. Electrons probably are
little affected, since they are delivered with an applicator
touching the skin. Wedged techniques or field-in-field
techniques seem insensitive for breathing motion, while
IMRT techniques are highly sensitive to movement [21].
Tomotherapy uses IMRT, but plan delivery accuracy
doesn't seem significantly affected by breathing [22].
The time per session for the patient on the treatment
table differs a lot between the different techniques. Based
on our clinical experience in our department, a treatment
with electrons mostly takes less than 5 minutes. The deliv-
ery of a photon boost with 2 or 3 fields or arc with Elekta
can take about 12 minutes. A treatment with Vero or
Tomotherapy on average takes 20 minutes. The difference
between the electron and photon treatments for a large
part is caused by the cone beam and image registration,
which is performed daily for all photon techniques.
Today, Vero and Tomotherapy proofed state of the
art. If not available, the 3-field photon technique showed
the best results. The use of an arc did not deliver a sub-
stantial benefit for the conformity, but did cause more
low dose spread. Electrons delivered a worse PTV cover-
age and more doses to the ipsilateral lung and heart.
However, there are a lot of things to be considered when
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use electrons, we choose the energy to encompass the
deepest border of the target volume with the 85% iso-
dose. In this analysis, we wanted to encompass the target
with the 95% isodose to be able to do a comparison with
photons. In daily practice, we would not give such a high
dose to the OAR as was shown in this work, but the
PTV coverage would be even worse. Although electrons
deliver a less optimal dose distribution and despite of
the fact that electrons are used for boost delivery rou-
tinely, no differences in local recurrences are seen be-
tween electron and photon boost techniques. In the
EORTC boost versus no boost trial [11] there was no
statistically significant difference in 5-year local failure
rates between electron and photon boost. Another con-
sideration is the localization of the target. Electrons are
not used in all situations. There were 2 patients with a
tumor bed located too deep to be covered with electrons
with energy of 15 MeV. In our department we would
choose a photon boost in these cases. One tumor bed
was located laterally, where the breast formed a fold. In
practice we would have repositioned the breast to have a
smooth surface, which could not be done on this CT-
based planning analysis, which resulted in an irrelative
dose distribution.
In 9 of the 10 patients, the PTV extended to the skin
surface. When you want to deliver dose at the skin sur-
face, it is important to choose a technique which has lit-
tle build-up. We see that a rotational technique has a
larger build-up area than the other techniques, except
for TomoTherapy. In case it is clinically important to
deliver dose at the skin surface, other techniques or the
use of a bolus should be considered. When the target is
located at the thoracic wall, rotational techniques tend
to spread low dose to a larger volume of the ipsilateral
lung and heart. In our choice for the most ideal tech-
nique, we should balance what is less damaging: a
slightly higher dose to a smaller part of the OAR or a
lower dose spread to a larger volume of the organ. For
the heart, dose dependent regional cardiac perfusion de-
fects are described [23]. Considering that part of the left
ventricle already has received 50 Gy with the wide tan-
gential fields, it would probably be better to minimize
the volume of heart receiving extra dose by the boost
delivery [20,24]. This means a technique that can avoid
delivering dose in the direction of the left ventricle
should be preferred. The same could be true for the ipsi-
lateral lung. Verbanck et al. [25] showed that regional
dysfunctions can be detected in the parts of the lung ir-
radiated with the wide tangential fields. When using
IMRT to minimize the dose to the lung, no changes
were detected. For the boost delivery, theoretically, it is
probably better to minimize the volume of ipsilateral
lung receiving extra dose and thus minimize the volumeat risk for damage. In practice, even with regional lung
dysfunctions measured, there were no subjective impli-
cations on breathing or physical efforts in all patients.
We reported the CI. We chose a formula which con-
siders both the over and under dosed areas [15]. However,
we do not know the ideal CI to aim for, since there is no
literature on this for breast irradiation. From this analysis,
our own conclusion is that a CI of 70% or more can be
considered as excellent, between 60% and 70% as good, be-
tween 50% and 60% as acceptable and less than 50% as bad
(cfr Table 2). The used formula for CI does not give a view
of the low dose spread. To have a more complete compari-
son of different techniques, you should analyze both the CI
and some measure of low dose spread. We looked at the
Vol20/Vol95 and to the Vol50/Vol95. The Vol20/Vol95
showed more differences for the different techniques, but
the Vol50/Vol95 is perhaps of more clinical meaning.
From this work we derived advices which can be used as
guidelines for selection of the best individualized boost
technique. If available, Vero should be used, since it was
the only technique that achieved an excellent PTV-
coverage and at the same time could minimize the dose to
the OAR. As a second choice, the TomoTherapy modal-
ities proved to be a good alternative. Special attention
should go to strict constraints to the OAR. A V5 < 2% to
the heart and < 15% to the ipsilateral lung and a D2 < 1 Gy
for the contralateral breast and < 3 Gy for the contralateral
lung should be aimed at. If no IMRT-IGRT technique is
available, the best choice depends on the localization of the
tumor bed. In case of a superficial tumor bed, reaching the
skin surface, one should avoid using a rotational technique,
unless bolus is used. In case of a deep tumor bed reaching
the thoracic wall, a 3-field technique is preferable. A
slightly higher dose will be given to a smaller volume of
the OAR, which is preferred above a rotational technique
which spreads a lower dose to al larger volume. In case the
tumor bed is surrounded by breast tissue, a conformal arc
can be preferred above a 3-field technique. An arc tech-
nique delivers a better conformity, though there is more
spread of very low dose to a larger volume of breast tissue.
In most cases a 2-field technique shows an unacceptable
conformity to be used in modern radiotherapy. Electrons
should be reserved for a very superficially located tumor
bed without contact with the thoracic wall. We strongly
advice to avoid the use of an energy higher than 12 MeV.
Conclusions
We performed a dosimetric comparison of different non-
invasive techniques to deliver an additional boost after
whole breast irradiation as part of the breast-conserving
therapy. Guidelines were presented. Standard procedures
should be replaced by an individualized treatment. The
presented guidelines can help to find the best treatment
technique for the individual patient.
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